Mersana Therapeutics (MRSN) Q2 2025 earnings summary

Executive summary

• Over 45 patients enrolled in Phase 1 dose expansion cohorts for Emi-Le in post-topo-1 TNBC, with initial data expected in H2 2025 and key data presented at ASCO and ESMO Breast Cancer 2025.

• Emi-Le demonstrated promising efficacy and manageable safety in B7-H4 high TNBC and ACC1, with positive interim data presented at major oncology conferences.

• XMT-2056 achieved a $15 million milestone payment from GSK, reflecting advancement in its phase I trial for HER2-expressing tumors.

• Strategic restructuring in May 2025 reduced workforce by 55% and narrowed R&D focus to breast cancer and collaborations.

• 1-for-25 reverse stock split effective July 25, 2025, regaining Nasdaq compliance.

Financial highlights

• Ended Q2 2025 with $77 million in cash and cash equivalents, down from $107.8 million at year-end 2024.

• Net loss for Q2 2025 was $24.3 million ($4.87/share), flat year-over-year.

• Collaboration revenue for Q2 2025 was $3.1 million, up from $2.3 million in Q2 2024, driven by J&J and Merck KGaA agreements.

• R&D expenses decreased to $16.2 million from $17.2 million year-over-year; G&A expenses declined to $7.4 million from $10.5 million.

• $3.9 million in restructuring charges recognized in Q2 2025.

Outlook and guidance

• Capital resources expected to fund operations into mid-2026, excluding future milestone or collaboration proceeds.

• Initial clinical data from Emi-Le expansion cohorts and XMT-2056 STING activation data anticipated in H2 2025.

• Ongoing efforts to secure additional capital through equity, debt, or strategic collaborations.